Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Invested Capital (2019 - 2025)

Lyell Immunopharma's Invested Capital history spans 7 years, with the latest figure at $298.9 million for Q2 2025.

  • For Q2 2025, Invested Capital fell 47.23% year-over-year to $298.9 million; the TTM value through Jun 2025 reached $298.9 million, down 47.23%, while the annual FY2024 figure was $382.8 million, 41.55% down from the prior year.
  • Invested Capital for Q2 2025 was $298.9 million at Lyell Immunopharma, down from $336.5 million in the prior quarter.
  • Across five years, Invested Capital topped out at $1.0 billion in Q2 2021 and bottomed at -$334.0 million in Q1 2021.
  • The 5-year median for Invested Capital is $717.2 million (2023), against an average of $644.4 million.
  • The largest annual shift saw Invested Capital surged 525.62% in 2021 before it tumbled 47.23% in 2025.
  • A 5-year view of Invested Capital shows it stood at $929.8 million in 2021, then fell by 10.38% to $833.3 million in 2022, then fell by 21.4% to $655.0 million in 2023, then plummeted by 41.55% to $382.8 million in 2024, then dropped by 21.92% to $298.9 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Invested Capital are $298.9 million (Q2 2025), $336.5 million (Q1 2025), and $382.8 million (Q4 2024).